Clinical trials: Indication for Anticoagulation

Stroke

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

• Terminated
• Age: 18 years and older
• Phase 3
• Medical device
• Results posted

The WAVECREST 2 trial is a prospective, multicenter, randomized, active controlled, clinical trial to evaluate the safety and effectiveness of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

Trial name

WAVECREST2 (NCT03302494)

Testing

Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device

Where

25 sites in United States, Australia

Volunteers

248 people

Sponsor

Coherex Medical